Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
On June 24, Nektar Therapeutics NASDAQ: NKTR stock exploded nearly 157% following news that Rezpeg, the company's experimental treatment for atopic dermatitis (eczema), successfully met its primary and secondary goals in a Phase 2b trial. Nektar joined a wave of micro-cap biotechnology stocks surging after promising clinical trial results.
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.
Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?
Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today's trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for treating moderate-to-severe atopic dermatitis (eczema), marking a pivotal moment for the cash-strapped biotech company. The study met both primary and secondary endpoints, validating the company's novel regulatory T-cell approach to treating inflammatory skin conditions.
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC
Results from Nektar Therapeutics' phase 2b REZOLVE-AD study, using REZPEG for the treatment of patients with atopic dermatitis, are expected in June 2025. The global atopic dermatitis treatment market is projected to reach $28.7 billion by 2031. NKTR's results from phase 2b REZOLVE-AA, using REZPEG for the treatment of patients with Alopecia Areata, expected in the 2nd half of 2025.
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Corinne Franklin – Investor Relations Howard Robin – President and Chief Executive Officer Jonathan Zalevsky – Chief Research and Development Officer Sandra Gardiner – Chief Financial Officer Conference Call Participants Dominic Risso-Gill – Piper Sandler Julian Harrison – BTIG Jay Olson – Oppenheimer Roger Song – Jefferies Mayank Mamtani – B. Riley Securities Arthur He – H.C.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago.
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.
